Survival and Outcome of Patients with Diffuse Large B-cell Lymphoma According to the Central Nervous System-International Prognostic Index.

IF 1.5 Q2 MEDICINE, GENERAL & INTERNAL
Musa Fares Alzahrani, Thamer Basahih, Ghazi Alotaibi, Sarah Sewaralthahab, Fatimah Alshalati, Ibrahim Alrumaih, Kazi Nur Asfina, Ahmed Gamal, Farjah Algahtani, Aamer Aleem
{"title":"Survival and Outcome of Patients with Diffuse Large B-cell Lymphoma According to the Central Nervous System-International Prognostic Index.","authors":"Musa Fares Alzahrani, Thamer Basahih, Ghazi Alotaibi, Sarah Sewaralthahab, Fatimah Alshalati, Ibrahim Alrumaih, Kazi Nur Asfina, Ahmed Gamal, Farjah Algahtani, Aamer Aleem","doi":"10.4103/sjmms.sjmms_654_24","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma. Several prognostic scores exist in DLBCL, including the International Prognostic Index (IPI). More recently, a modification of the IPI that estimates the risk of progression to the central nervous system (CNS-IPI) was published. Whether the CNS-IPI index is sufficient to prognosticate DLBCL survival is yet untested.</p><p><strong>Objectives: </strong>We aim to describe the outcomes of DLBCL patients based on CNS-IPI risk groups.</p><p><strong>Methods: </strong>We retrospectively reviewed all DLBCL cases diagnosed from January 2015 until April 2022 at an academic tertiary hospital in Riyadh, Saudi Arabia. CNS-IPI was calculated at the time of diagnosis. The outcomes were compared between two CNS-IPI risk categories: low and intermediate/high-risk groups. Logrank method was used to calculate <i>P</i> value, and Kaplan-Meier method to estimate survival.</p><p><strong>Results: </strong>A total of 136 patients were included (median age: 56.5 years), of which 38 (28%) died: 5 in the low-risk group and 33 in the intermediate/high-risk group. Low-risk and intermediate/high-risk CNS-IPI were found in 41 (30%) and 95 (70%) patients, respectively. The median survival in the low-risk and intermediate/high-risk CNS-IPI groups was 66 months [95% CI: 60-not-reached (NR)] and NR (95% CI: 24-NR) (<i>P</i> = 0.007), respectively. Only seven (5%) patients developed progression to the CNS, of which 6 (86%) were in the intermediate/high-risk group.</p><p><strong>Conclusion: </strong>The risk of progression to the central nervous system was moderate in our diffuse large B-cell lymphoma population. Patients with intermediate/high-risk CNS-IPI had worse survival compared with low-risk patients. The CNS-IPI was found to a good model to not only estimate the risk of disease progression to the central nervous system but also overall survival.</p>","PeriodicalId":21442,"journal":{"name":"Saudi Journal of Medicine & Medical Sciences","volume":"13 3","pages":"205-209"},"PeriodicalIF":1.5000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12366903/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Saudi Journal of Medicine & Medical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/sjmms.sjmms_654_24","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/14 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma. Several prognostic scores exist in DLBCL, including the International Prognostic Index (IPI). More recently, a modification of the IPI that estimates the risk of progression to the central nervous system (CNS-IPI) was published. Whether the CNS-IPI index is sufficient to prognosticate DLBCL survival is yet untested.

Objectives: We aim to describe the outcomes of DLBCL patients based on CNS-IPI risk groups.

Methods: We retrospectively reviewed all DLBCL cases diagnosed from January 2015 until April 2022 at an academic tertiary hospital in Riyadh, Saudi Arabia. CNS-IPI was calculated at the time of diagnosis. The outcomes were compared between two CNS-IPI risk categories: low and intermediate/high-risk groups. Logrank method was used to calculate P value, and Kaplan-Meier method to estimate survival.

Results: A total of 136 patients were included (median age: 56.5 years), of which 38 (28%) died: 5 in the low-risk group and 33 in the intermediate/high-risk group. Low-risk and intermediate/high-risk CNS-IPI were found in 41 (30%) and 95 (70%) patients, respectively. The median survival in the low-risk and intermediate/high-risk CNS-IPI groups was 66 months [95% CI: 60-not-reached (NR)] and NR (95% CI: 24-NR) (P = 0.007), respectively. Only seven (5%) patients developed progression to the CNS, of which 6 (86%) were in the intermediate/high-risk group.

Conclusion: The risk of progression to the central nervous system was moderate in our diffuse large B-cell lymphoma population. Patients with intermediate/high-risk CNS-IPI had worse survival compared with low-risk patients. The CNS-IPI was found to a good model to not only estimate the risk of disease progression to the central nervous system but also overall survival.

Abstract Image

Abstract Image

根据中枢神经系统-国际预后指数,弥漫性大b细胞淋巴瘤患者的生存和预后。
背景:弥漫性大b细胞淋巴瘤(DLBCL)是最常见的非霍奇金淋巴瘤类型。DLBCL中存在几种预后评分,包括国际预后指数(IPI)。最近,对IPI进行了修改,用于估计中枢神经系统进展的风险(CNS-IPI)。CNS-IPI指数是否足以预测DLBCL的生存尚未得到检验。目的:我们的目的是描述基于CNS-IPI风险组的DLBCL患者的预后。方法:我们回顾性分析了沙特阿拉伯利雅得一家三级医院2015年1月至2022年4月诊断的所有DLBCL病例。在诊断时计算CNS-IPI。比较两种CNS-IPI风险类别:低和中/高风险组的结果。采用Logrank法计算P值,Kaplan-Meier法估计生存率。结果:共纳入136例患者(中位年龄:56.5岁),其中38例(28%)死亡:低危组5例,中高危组33例。低危和中/高危CNS-IPI患者分别为41例(30%)和95例(70%)。低危和中/高危CNS-IPI组的中位生存期分别为66个月[95% CI: 60-未达到(NR)]和NR (95% CI: 24-NR) (P = 0.007)。只有7例(5%)患者进展到中枢神经系统,其中6例(86%)属于中/高危组。结论:弥漫性大b细胞淋巴瘤患者进展到中枢神经系统的风险中等。中/高危CNS-IPI患者的生存率较低危患者差。发现CNS-IPI不仅是估计疾病进展到中枢神经系统的风险,而且是估计总体生存的良好模型。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Saudi Journal of Medicine & Medical Sciences
Saudi Journal of Medicine & Medical Sciences MEDICINE, GENERAL & INTERNAL-
CiteScore
1.40
自引率
0.00%
发文量
52
审稿时长
15 weeks
期刊介绍: Saudi Journal of Medicine & Medical Sciences (SJMMS) is the official scientific journal of Imam Abdulrahman Bin Faisal University. It is an international peer-reviewed, general medical journal. The scope of the Journal is to publish research that will be of interest to health specialties both in academic and clinical practice. The Journal aims at disseminating high-powered research results with the objective of turning research into knowledge. It seeks to promote scholarly publishing in medicine and medical sciences. The Journal is published in print and online. The target readers of the Journal include all medical and health professionals in the health cluster such as in medicine, dentistry, nursing, applied medical sciences, clinical pharmacology, public health, etc.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信